Most sold healthcare stocks in Q4 2020
See which Healthcare stocks institutional investors trimmed or exited the most in Q4 2020, measured as net reductions in reported share positions from Q3 2020 into Q4 2020. Notable reductions at the top of this list include ASTRAZENECA PLC-SPONS ADR (AZN), BRISTOL-MYERS SQUIBB CO (BMY), CENTENE CORP (CNC), AKEBIA THERAPEUTICS INC (AKBA). These rankings aggregate SEC 13F filings from all institutional investors in our database.
Explore more:
| Symbol | Name | Net shares | Net value | New | Added | Trimmed | Sold out | Holding now |
|---|---|---|---|---|---|---|---|---|
| AZN | ASTRAZENECA PLC-SPONS ADR | -11,764,818 | -$666.50M | 1 | 1 | 3 | 0 | 6 |
| BMY | BRISTOL-MYERS SQUIBB CO | -9,857,578 | -$446.47M | 1 | 12 | 7 | 1 | 21 |
| CNC | CENTENE CORP | -4,862,784 | -$260.90M | 1 | 1 | 5 | 0 | 7 |
| AKBA | AKEBIA THERAPEUTICS INC | -4,258,710 | -$10.26M | 1 | 1 | 0 | 1 | 2 |
| PFE | PFIZER INC | -3,748,288 | -$168.50M | 3 | 10 | 6 | 2 | 19 |
| ABBV | ABBVIE INC | -2,981,096 | $368.88M | 4 | 10 | 4 | 0 | 22 |
| ADPT | ADAPTIVE BIOTECHNOLOGIES | -2,834,019 | $193.40M | 1 | 1 | 1 | 0 | 3 |
| NVS | NOVARTIS AG-SPONSORED ADR | -2,135,579 | $3.86M | 1 | 2 | 8 | 0 | 11 |
| TEVA | TEVA PHARMACEUTICAL-SP ADR | -2,079,548 | $28.92M | 2 | 1 | 4 | 1 | 9 |
| MCK | MCKESSON CORP | -1,871,208 | -$191.32M | 2 | 3 | 1 | 1 | 6 |
| JNJ | JOHNSON & JOHNSON | -1,836,693 | -$154.31M | 3 | 9 | 7 | 1 | 25 |
| ALGN | ALIGN TECHNOLOGY INC | -1,462,196 | $568.39M | 2 | 4 | 5 | 0 | 12 |
| LAB | STANDARD BIOTOOLS INC | -1,452,900 | -$11.88M | 1 | 0 | 1 | 0 | 2 |
| ZNTL | ZENTALIS PHARMACEUTICALS INC | -1,425,603 | $11.49M | 1 | 0 | 1 | 0 | 2 |
| CVS | CVS HEALTH CORP | -1,360,622 | $125.56M | 3 | 11 | 5 | 2 | 20 |
| HUM | HUMANA INC | -1,321,648 | -$558.61M | 2 | 1 | 3 | 0 | 6 |
| NVO | NOVO-NORDISK A/S-SPONS ADR | -1,268,548 | -$77.15M | 1 | 0 | 3 | 0 | 7 |
| OSUR | ORASURE TECHNOLOGIES INC | -1,189,307 | -$16.31M | 0 | 0 | 1 | 0 | 1 |
| TMO | THERMO FISHER SCIENTIFIC INC | -1,084,286 | -$453.97M | 3 | 6 | 5 | 1 | 17 |
| ALT | ALTIMMUNE INC | -1,024,507 | -$13.52M | 0 | 0 | 0 | 1 | 0 |
| EXEL | EXELIXIS INC | -941,185 | -$118.75M | 1 | 2 | 1 | 0 | 4 |
| VRTX | VERTEX PHARMACEUTICALS INC | -914,229 | -$418.44M | 1 | 3 | 2 | 0 | 6 |
| EHC | ENCOMPASS HEALTH CORP | -745,598 | -$2.86M | 0 | 1 | 2 | 1 | 3 |
| BIIB | BIOGEN INC | -720,715 | -$362.27M | 0 | 5 | 1 | 1 | 8 |
| CLDX | CELLDEX THERAPEUTICS INC | -687,848 | -$7.38M | 0 | 0 | 1 | 0 | 1 |
| EW | EDWARDS LIFESCIENCES CORP | -683,689 | -$43.94M | 1 | 5 | 4 | 1 | 10 |
| ATYR | ATYR PHARMA INC | -676,744 | -$1.98M | 0 | 0 | 1 | 1 | 1 |
| EDIT | EDITAS MEDICINE INC | -650,960 | $407.51M | 0 | 0 | 1 | 1 | 1 |
| LXRX | LEXICON PHARMACEUTICALS INC | -637,652 | $1.05M | 0 | 0 | 1 | 0 | 1 |
| RVP | RETRACTABLE TECHNOLOGIES INC | -615,171 | -$21.00K | 0 | 0 | 1 | 0 | 1 |
| CAH | CARDINAL HEALTH INC | -555,446 | -$2.48M | 1 | 2 | 4 | 0 | 7 |
| ATRC | ATRICURE INC | -550,465 | -$21.63M | 1 | 0 | 1 | 0 | 2 |
| INVA | INNOVIVA INC | -512,809 | $9.93M | 0 | 0 | 1 | 0 | 1 |
| PDCO | PATTERSON COS INC | -509,521 | -$20.71M | 1 | 1 | 1 | 1 | 4 |
| LLY | ELI LILLY & CO | -507,866 | -$63.48M | 1 | 5 | 3 | 1 | 10 |
| HALO | HALOZYME THERAPEUTICS INC | -473,407 | -$3.44M | 0 | 3 | 0 | 1 | 3 |
| ELV | ELEVANCE HEALTH INC | -455,171 | $300.40M | 2 | 3 | 7 | 1 | 14 |
| MOH | MOLINA HEALTHCARE INC | -450,832 | $37.74M | 0 | 0 | 4 | 0 | 4 |
| BKD | BROOKDALE SENIOR LIVING INC | -446,200 | $21.12M | 1 | 0 | 1 | 0 | 2 |
| RVTY | REVVITY INC | -444,727 | -$55.16M | 1 | 1 | 1 | 1 | 3 |
| LCTX | LINEAGE CELL THERAPEUTICS IN | -437,806 | -$392.00K | 0 | 0 | 1 | 0 | 1 |
| ADAP | ADAPTIMMUNE THERAPEUTICS-ADR | -429,516 | -$5.74M | 0 | 0 | 1 | 0 | 1 |
| VERU | VERU INC | -414,492 | -$958.00K | 0 | 0 | 1 | 0 | 1 |
| PINC | PREMIER INC-CLASS A | -408,774 | -$5.77M | 0 | 0 | 1 | 0 | 1 |
| VNDA | VANDA PHARMACEUTICALS INC | -380,946 | $10.24M | 1 | 0 | 1 | 0 | 2 |
| AMGN | AMGEN INC | -375,313 | -$132.83M | 1 | 8 | 3 | 1 | 13 |
| HAE | HAEMONETICS CORP/MASS | -361,095 | $17.83M | 0 | 0 | 2 | 0 | 2 |
| CRL | CHARLES RIVER LABORATORIES | -356,895 | -$64.40M | 1 | 1 | 2 | 0 | 4 |
| GMAB | GENMAB A/S -SP ADR | -347,183 | -$6.22M | 0 | 1 | 3 | 0 | 4 |
| NBIX | NEUROCRINE BIOSCIENCES INC | -339,851 | -$35.22M | 1 | 1 | 2 | 0 | 4 |
Frequently asked questions about Most sold healthcare stocks in Q4 2020
What are the most sold Healthcare stocks in Q4 2020?
The most sold healthcare stocks in Q4 2020 are those with the largest decrease in reported share counts across institutional investors compared to Q3 2020, based on SEC 13F filings.
Which healthcare stocks did institutional investors trimmed or exited the most in Q4 2020?
Among filers in this sector, net reductions were largest in companies such as ASTRAZENECA PLC-SPONS ADR (AZN), BRISTOL-MYERS SQUIBB CO (BMY), CENTENE CORP (CNC), based on aggregated 13F data.
How is institutional selling calculated?
Selling is calculated by summing the net decrease in shares reported by institutional investors between two consecutive quarterly 13F snapshots (compared to Q3 2020).
Does this include all institutional owners?
Yes. These rankings aggregate SEC 13F filings from all institutional investors in our database, not only the investors we track individually.
Are these trades real-time?
No. 13F filings are reported quarterly and may be delayed by up to 45 days. The data reflects positions at the end of the reporting period, not real-time trading activity.